Abstract
Pfitzenmaier and Altwein in their very readable article explain the advantage of hormone therapy in locally advanced prostate cancer with an unfavourable Gleason score. Further, they show in a table the extent to which a PSA increase may give an indication of a poorer prognosis. For the question that is crucial when recommending routine PSA measurements be used in tumor aftercare-namely, which treatment option should be chosen when PSA rises-the authors take recourse to the worst possible evidence-expert opinion (EAU guideline 2008). They do not provide a real proof for why after primary treatment for prostate cancer PSA should be measured and which order of benefit therapy would yield that is administered after a rise in PSA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
